Eph-ephrin signalling in adult tissues and cancer

Current Opinion in Cell Biology

Volumn 20, Issue 2, 2008, Pages 194-200

  Merlos Suárez, Anna ^a   Batlle, Eduard ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN B1; EPHRIN B2; EPHRIN B3; EPHRIN RECEPTOR; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A5; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B4; EPHRIN RECEPTOR B6;

BLOOD CELL; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; COLORECTAL CANCER; GLIOMA; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW;

EPHRINS; HUMANS; MORPHOGENESIS; NEOPLASMS; ORGAN SPECIFICITY; RECEPTORS, EPH FAMILY; SIGNAL TRANSDUCTION;

EID: 41549139097     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceb.2008.01.011     Document Type: Review

References (54)

1. Pasquale E.B. Eph-ephrin promiscuity is now crystal clear. Nat Neurosci 7 (2004) 417-418
2. Kullander K., and Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3 (2002) 475-486
3. Pasquale E.B. EPH receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6 (2005) 462-475
4. Palmer A., and Klein R. Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes Dev 17 (2003) 1429-1450
5. Yamaguchi Y., and Pasquale E.B. Eph receptors in the adult brain. Curr Opin Neurobiol 14 (2004) 288-296
6. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, et al.: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:1003-10U1. Identification of ISCs in the crypts by genetic analysis. This paper shows for the first time that ISCs reside at the crypt base intermingled with PCs, instead of at +4 position as previously thought.
7. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der H.K., Batlle E., Coudreuse D., Haramis A.P., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111 (2002) 241-250
8. van Es J.H., Jay P., Gregorieff A., van Gijn M.E., Jonkheer S., Hatzis P., Thiele A., van den Born M., Begthel H., Brabletz T., et al. Wnt signalling induces maturation of Paneth cells in intestinal crypts. Nat Cell Biol 7 (2005) 381-437
9. Clevers H., and Batlle E. EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res 66 (2006) 2-5
10. Gregorieff A., and Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 19 (2005) 877-890
11. Batlle E., Henderson J.T., Beghtel H., van den Born M.M., Sancho E., Huls G., Meeldijk J., Robertson J., van de W.M., Pawson T., et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111 (2002) 251-263. First description of intestinal phenotypes in EphB2 and EphB3 mutant mice. The observations described here imply that not all the instructions codified by beta-catenin/Tcf genetic programme regulate cell growth. Apparently, Wnt signalling also controls cell positioning in the crypts by regulating the expression domains of EphB receptors and ephrinB ligands.
12. Cortina C., Palomo-Ponce S., Iglesias M., Fernandez-Masip J.L., Vivancos A., Whissell G., Huma M., Peiro N., Gallego L., Jonkheer S., et al. EphB-ephrinB interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet 39 (2007) 1376-1383. This paper shows that tumor cells that express EphB receptors cannot colonize ephrinB1 positive areas of the intestine. This phenomenon is described as tumor compartmentalization and results in tumor suppression in the colon. The mechanism depends on the ability of EphB signalling to enforce E-cadherin adhesion.
13. Holmberg J., Genander M., Halford M.M., Anneren C., Sondell M., Chumley M.J., Silvany R.E., Henkemeyer M., and Frisen J. EphB receptors coordinate migration and proliferation in the intestinal stem cell niche. Cell 125 (2006) 1151-1163. Describes defects in cell proliferation in the intestine of EphB2/-B3 mutant mice which apparently are not linked to cell positioning alterations. This article suggests a role for EphB signalling in inducing cell proliferation. It would be interesting to reinterpret these observations in light of the identification of ISCs in the crypt base and of the re-distribution of cell types present in EphB mutant mice.
14. Andres A.C., and Ziemiecki A. Eph and ephrin signaling in mammary gland morphogenesis and cancer. J Mammary Gland Biol 8 (2003) 475-485
15. Munarini N., Jager R., Abderhalden S., Zuercher G., Rohrbach V., Loercher S., Pfanner-Meyer B., Andres A.C., and Ziemiecki A. Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. J Cell Sci 115 (2002) 25-37
16. Ogawa K., Wada H., Okada N., Harada I., Nakajima T., Pasquale E.B., and Tsuyama S. EphB2 and ephrin-B1 expressed in the adult kidney regulate the cytoarchitecture of medullary tubule cells through Rho family GTPases. J Cell Sci 119 (2006) 559-570
17. Prevost N., Woulfe D.S., Jiang H., Stalker T.J., Marchese P., Ruggeri Z.M., and Brass L.F. Eph kinases and ephrins support thrombus growth and stability by regulating integrin outside-in signaling in platelets. Proc Natl Acad Sci U S A 102 (2005) 9820-9825. Describes the requirement of Eph-ephrin signalling for the proper growth and stability of platelet aggregates in thrombus.
18. Luo H.Y., Yu G., Tremblay J., and Wu J.P. EphB6-null mutation results in compromised T cell function. J Clin Invest 114 (2004) 1762-1773
19. Yu G., Mao J.N., Wu Y.L., Luo H.Y., and Wu J.P. Ephrin-B1 is critical in T-cell development. J Biol Chem 281 (2006) 10222-10229
20. Yu G., Luo H.Y., Wu Y.L., and Wu J.P. Ephrin B2 induces T cell costimulation. J Immunol 171 (2003) 106-114
21. Konstantinova I., Nikolova G., Ohara-Imaizumi M., Meda P., Kucera T., Zarbalis K., Wurst W., Nagamatsu S., and Lammert E. EphA-ephrinA-mediated beta cell communication regulates insulin secretion from pancreatic islets. Cell 129 (2007) 359-370. This is the only report to date describing a role for Ephs and ephrins in the pancreas. It shows in vivo requirement of Eph-ephrin signalling in an exocytotic event. This observation may have therapeutic implications for treatment of diabetes.
22. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 17 (2007) 45-51
23. Van der Flier L.G., Sabates-Bellver J., Oving I., Haegebarth A., De P.M., Anti M., van Gijn M.E., Suijkerbuijk S., van de W.M., Marra G., et al. The Intestinal Wnt/TCF Signature. Gastroenterology 132 (2007) 628-632. A systematic description and analysis of beta-catenin/Tcf target genes in intestinal crypts.
24. Batlle E., Bacani J., Begthel H., Jonkeer S., Gregorieff A., van de Born M., Malats N., Sancho E., Boon E., Pawson T., et al. EphB receptor activity suppresses colorectal cancer progression. Nature 435 (2005) 1126-1130. First description of EphB2, EphB3 and EphB4 silencing in CRC and in vivo demonstration using animal models of CRC that blockage of EphB activity plays an important role in the adenoma-carcinoma transition.
25. Guo D.L., Zhang J., Yuen S.T., Tsui W.Y., Chan A.S., Ho C., Ji J., Leung S.Y., and Chen X. Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 27 (2006) 454-464
26. Jubb A.M., Zhong F., Bheddah S., Grabsch H.I., Frantz G.D., Mueller W., Kavi V., Quirke P., Polakis P., and Koeppen H. EphB2 is a prognostic factor in colorectal cancer. Clin Cancer Res 11 (2005) 5181-5187
27. Lugli A., Spichtin H., Maurer R., Mirlacher M., Kiefer J., Huusko P., Azorsa D., Terracciano L., Sauter G., Kallioniemi O.P., et al. EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res 11 (2005) 6450-6458
28. Alazzouzi H., Davalos V., Kokko A., Domingo E., Woerner S.M., Wilson A.J., Konrad L., Laiho P., Espin E., Armengol M., et al. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65 (2005) 10170-10173
29. Davalos V, Dopeso H, Castano J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espin E, Armengol M, Capella G, Mariadason JM, et al.: EPHB4 and survival of colorectal cancer patients. Cancer Res 2006, 66:8943-8948.
30. Kaidi A., Moorghen M., Williams A.C., and Paraskeva C. Is the downregulation of EphB2 receptor expression during colorectal tumorigenesis due to hypoxia?. Gut 56 (2007) 1637-1638
31. Huusko P., Ponciano-Jackson D., Wolf M., Kiefer J.A., Azorsa D.O., Tuzmen S., Weaver D., Robbins C., Moses T., Allinen M., et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 36 (2004) 979-983
32. Kittles R.A., Baffoe-Bonnie A.B., Moses T.Y., Robbins C.M., Ahaghotu C., Huusko P., Pettaway C., Vijayakumar S., Bennett J., Hoke G., et al. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 43 (2006) 507-511
33. Brantley-Sieders D.M., Zhuang G.L., Hicks D.J., Fang W.B., Hwang Y., Cates J.M.M., Coffman K., Jackson D., Bruckheimer E., Muraoka-Cook R.S., et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest (2007). ErbB2-induced tumorigenesis is enhanced in the presence of EphA2. The authors show that ErbB2 and EphA2 interact and activate Ras-MAPK and Rho GTPases, thus promoting tumor cell proliferation and motility. This work enhances the notion that Eph oncogenic potential depends on the cellular context.
34. Ireton R.C., and Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Tar 5 (2005) 149-157
35. Noren N.K., Foos G., Hauser C.A., and Pasquale E.B. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8 (2006) 815-825. This work reveals a tumor suppressor role for EphB4 receptor in breast cancer and identifies the Abl-Crk pathway as the main effector of EphB4-induced inhibition of proliferation and cell migration.
36. Nakada M., Niska J.A., Miyamori H., McDonough W.S., Wu J., Sato H., and Berens M.E. Phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res 64 (2004) 3179-3185
37. Nakada M., Niska J.A., Tran N.L., McDonough W.S., and Berens M.E. EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol 167 (2005) 565-576
38. Nakada M., Drake K.L., Nakada S., Niska J.A., and Berens M.E. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res 66 (2006) 8492-8500
39. Kuijper S., Turner C.J., and Adams R.H. Regulation of angiogenesis by Eph-Ephrin interactions. Trends Cardiovas Med 17 (2007) 145-151
40. Foo S.S., Turner C.J., Adams S., Compagni A., Aubyn D., Kogata N., Lindblom P., Shani M., Zicha D., and Adams R.H. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell 124 (2006) 161-173. Mural cells (pericytes and vascular smooth muscle cells) are essential for the assembly of stable blood vessels. Specific inactivation in these cells reveals that ephrinB2 expression is critical for the association of mural cells to the walls of blood vessels, a key event during blood vascular morphogenesis.
41. Makinen T., Adams R.H., Bailey J., Lu Q., Ziemiecki A., Alitalo K., Klein R., and Wilkinson G.A. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev 19 (2005) 397-410
42. Erber R., Eichelsbacher U., Powajbo V., Korn T., Djonov V., Lin J.H., Hammes H.P., Grobholz R., Ullrich A., and Vajkoczy P. EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J 25 (2006) 628-641
43. Gale N.W., Baluk P., Pan L., Kwan M., Holash J., DeChiara T.M., McDonald D.M., and Yancopoulos G.D. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 230 (2001) 151-160
44. Shin D., Garcia-Cardena G., Hayashi S.I., Gerety S., Asahara T., Stavrakis G., Isner J., Folkman J., Gimbrone M.A., and Anderson D.J. Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev Biol 230 (2001) 139-150
45. Noren N.K., Lu M., Freeman A.L., Koolpe M., and Pasquale E.B. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. P Natl Acad Sci U S A 101 (2004) 5583-5588
46. Ogawa K., Pasqualini R., Lindberg R.A., Kain R., Freeman A.L., and Pasquale E.B. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19 (2000) 6043-6052
47. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J: Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 2005, 19:1884.
48. Brantley-Sieders D.M., Fang W.B., Hwang Y., Hicks D., and Chen J. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 66 (2006) 10315-10324
49. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274. Determination of the complete coding sequences of different breast and colorectal cancers. This work identifies EphB6 and EphA3 as two of the genes most frequently mutated in CRC.
50. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., Teague B., Butler A., Edkins S., Stevens C., et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65 (2005) 7591-7595
51. Wang J.D., Kataoka H., Suzuki M., Sato N., Nakamura R., Tao H., Maruyama K., Isogaki J., Kanaoka S., Ihara M., et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 24 (2005) 5637-5647
52. Wang J.D., Li G.L., Ma H.H., Bao Y., Wang X.L., Zhou H.B., Sheng Z., Sugimura H., Jin J., and Zhou X.J. Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum Pathol 38 (2007) 1649-1656
53. Dawson D.W., Hong J.S., Shen R.R., French S.W., Troke J.J., Wu Y.Z., Chen S.S., Gui D., Regelson M., Marahrens Y., et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 26 (2007) 4243-4252
54. Davalos V., Dopeso H., Velho S., Ferreira A.M., Cirnes L., Díaz-Chico N., Bilbao C., Ramírez R., Rodríguez G., Falcón O., et al. High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene 26 (2007) 308-311